EP Patent

EP3651801A1 — Compositions and methods for the treatment of fungal infections

Assigned to NAPP PHARMACEUTICAL GROUP Ltd · Expires 2020-05-20 · 6y expired

What this patent protects

The invention relates to non-irritating pharmaceutical compositions containing CD101 in a pharmaceutically acceptable salt (e.g., CD101 acetate) or a neutral form. The pharmaceutical compositions may be administered intravenously to a subject for treating fungal infections (eg, c…

USPTO Abstract

The invention relates to non-irritating pharmaceutical compositions containing CD101 in a pharmaceutically acceptable salt (e.g., CD101 acetate) or a neutral form. The pharmaceutical compositions may be administered intravenously to a subject for treating fungal infections (eg, candidiasis) in the subject.

Drugs covered by this patent

Patent Metadata

Patent number
EP3651801A1
Jurisdiction
EP
Classification
—
Expires
2020-05-20
Drug substance claim
No
Drug product claim
No
Assignee
NAPP PHARMACEUTICAL GROUP Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.